RGC-32 is a novel regulator of the T-lymphocyte cell cycle

Experimental and Molecular Pathology

Volumn 98, Issue 3, 2015, Pages 328-337

  Tegla, Cosmin A ^a,b   Cudrici, Cornelia D ^a   Nguyen, Vinh ^a   Danoff, Jacob ^a   Kruszewski, Adam M ^a   Boodhoo, Dallas ^a   Mekala, Armugam P ^a   Vlaicu, Sonia I ^a,d   Chen, Ching ^a   Rus, Violeta ^a   Badea, Tudor C ^c   Rus, Horea ^a,b,e  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NATIONAL EYE INSTITUTE   (United States)

^d IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e Veterans Administration Multiple Sclerosis Center of Excellence   (United States)

Author keywords

Akt; Cell cycle; IL 2; Knockout mouse; RGC 32; T cells

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CD28 ANTIBODY; CD28 ANTIGEN; CD3 ANTIBODY; CD4 ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2; KI 67 ANTIGEN; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN ANTIBODY; PROTEIN KINASE B; REGULATOR PROTEIN; RESPONSE GENE TO COMPLEMENT 32 PROTEIN; T LYMPHOCYTE RECEPTOR; THYMIDINE; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, MOUSE; MORPHOLINE DERIVATIVE; NUCLEAR PROTEIN; PROTEIN KINASE INHIBITOR; RGC-32 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL CYCLE REGULATION; CONTROLLED STUDY; FEMALE; KNOCKOUT MOUSE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SPLEEN CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CYCLE; CYTOLOGY; DRUG EFFECTS; GENETICS; METABOLISM;

MUS;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL CYCLE; CHROMONES; FORKHEAD TRANSCRIPTION FACTORS; INTERLEUKIN-2; KI-67 ANTIGEN; MICE; MICE, INBRED C57BL; MORPHOLINES; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER;

EID: 84926317230     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.03.011     Document Type: Article

References (34)

1. An X., et al. Response gene to complement 32, a novel hypoxia-regulated angiogenic inhibitor. Circulation 2009, 120:617-627.
2. Appleman L.J., et al. CD28 costimulation mediates down-regulation of p27kip1 and cell cycle progression by activation of the PI3K/PKB signaling pathway in primary human T cells. J. Immunol. 2002, 168:2729-2736.
3. Badea T.C., et al. Molecular cloning and characterization of RGC-32, a novel gene induced by complement activation in oligodendrocytes. J. Biol. Chem. 1998, 273:26977-26981.
4. Badea T., et al. RGC-32 increases p34CDC2 kinase activity and entry of aortic smooth muscle cells into S-phase. J. Biol. Chem. 2002, 277:502-508.
5. Brunet A., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-868.
6. Cudrici C., et al. Dendritic cells are abundant in non-lesional gray matter in multiple sclerosis. Exp. Mol. Pathol. 2007, 83:198-206.
7. Cudrici C., et al. Complement C5 regulates the expression of insulin-like growth factor binding proteins in chronic experimental allergic encephalomyelitis. J. Neuroimmunol. 2008, 203:94-103.
8. Cui X.B., et al. Response gene to complement 32 deficiency causes impaired placental angiogenesis in mice. Cardiovasc. Res. 2013, 99:632-639.
9. Datta S.R., et al. Cellular survival: a play in three Akts. Genes Dev. 1999, 13:2905-2927.
10. Fosbrink M., et al. Overexpression of RGC-32 in colon cancer and other tumors. Exp. Mol. Pathol. 2005, 78:116-122.
11. Fosbrink M., et al. C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of Forkhead transcription factor FOXO1. J. Biol. Chem. 2006, 281:19009-19018.
12. Fosbrink M., et al. Response gene to complement 32 is required for C5b-9 induced cell cycle activation in endothelial cells. Exp. Mol. Pathol. 2009, 86:87-94.
13. Fung M.M., et al. IL-2 activation of a PI3K-dependent STAT3 serine phosphorylation pathway in primary human T cells. Cell. Signal. 2003, 15:625-636.
14. Huang W.-Y., et al. RGC-32 mediates transforming growth factor-Î2-induced epithelial-mesenchymal transition in human renal proximal tubular cells. J. Biol. Chem. 2009, 284:9426-9432.
15. Ito Y., Miyazono K. RUNX transcription factors as key targets of TGF-[beta] superfamily signaling. Curr. Opin. Genet. Dev. 2003, 13:43-47.
16. Jakowlew S.B. Transforming growth factor-beta in cancer and metastasis. Cancer Metastasis Rev. 2006, 25:435-457.
17. Jones R.G., et al. Protein kinase B regulates T lymphocyte survival, nuclear factor kappaB activation, and Bcl-X(L) levels in vivo. J. Exp. Med. 2000, 191:1721-1734.
18. Kane L.P., et al. Akt provides the CD28 costimulatory signal for up-regulation of IL-2 and IFN-gamma but not TH2 cytokines. Nat. Immunol. 2001, 2:37-44.
19. Machida S., et al. Forkhead transcription factor FoxO1 transduces insulin-like growth factor's signal to p27Kip1 in primary skeletal muscle satellite cells. J. Cell. Physiol. 2003, 196:523-531.
20. Nguyen V., et al. IL-21 promotes lupus-like disease in chronic graft-versus-host disease through both CD4 T cell- and B cell-intrinsic mechanisms. J. Immunol. 2012, 189:1081-1093.
21. Niculescu F., et al. Activation of Ras and mitogen-activated protein kinase pathway by terminal complement complexes is G protein dependent. J. Immunol. 1997, 158:4405-4412.
22. Pages F., et al. Binding of phosphatidylinositol-3-OH kinase to CD28 is required for T-cell signalling. Nature 1994, 369:327-329.
23. Park E.S., et al. Response gene to complement 32 expression is induced by the luteinizing hormone (LH) surge and regulated by LH-induced mediators in the rodent ovary. Endocrinology 2008, 149:3025-3036.
24. Potente M., et al. 11,12-Epoxyeicosatrienoic acid-induced inhibition of FOXO factors promotes endothelial proliferation by down-regulating p27Kip1. J. Biol. Chem. 2003, 278:29619-29625.
25. Rathmell J.C., et al. Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma. Eur. J. Immunol. 2003, 33:2223-2232.
26. Salih D.A., Brunet A. FoxO transcription factors in the maintenance of cellular homeostasis during aging. Curr. Opin. Cell Biol. 2008, 20:126-136.
27. Stahl M., et al. The Forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J. Immunol. 2002, 168:5024-5031.
28. Tanaka T., et al. Distinct gene expression patterns of peripheral blood cells in hyper-IgE syndrome. Clin. Exp. Immunol. 2005, 140:524-531.
29. Tegla C.A., et al. Dual role of response gene to complement-32 in multiple sclerosis. Exp. Mol. Pathol. 2013, 94:17-28.
30. Tzivion G., et al. FoxO transcription factors; regulation by AKT and 14-3-3 proteins. Biochim. Biophys. Acta 2011, 1813:1938-1945.
31. Vlaicu S.I., et al. Role of response gene to complement 32 in diseases. Arch. Immunol. Ther. Exp. (Warsz) 2008, 56:115-122.
32. Vlaicu S.I., et al. Epigenetic modifications induced by RGC-32 in colon cancer. Exp. Mol. Pathol. 2010, 88:67-76.
33. Ward S.G., et al. Ligation of CD28 receptor by B7 induces formation of D-3 phosphoinositides in T lymphocytes independently of T cell receptor/CD3 activation. Eur. J. Immunol. 1993, 23:2572-2577.
34. Wotton S., et al. Gene array analysis reveals a common Runx transcriptional programme controlling cell adhesion and survival. Oncogene 2008, 27:5856-5866.